Market Overview:
The global liposomal irinotecan market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for targeted therapies, and technological advancements in the field of liposomal irinotecan. Based on type, the global liposomal irinotecan market is segmented into 43mg and 50mg. The 43mg segment is expected to account for a larger share of the market than the 50mg segment during the forecast period. This can be attributed to its lower price point and growing demand for low-cost therapies. Based on application, the global liposomal irinotecan market is divided into hospital and drugs store segments.
Product Definition:
Liposomal irinotecan is a form of the cancer drug irinotecan that is encased in liposomes. Liposomes are tiny bubbles of fat that can carry drugs into cells. This makes the drug more effective and less likely to cause side effects.
43mg:
43 mg is a form of Liposomal Irinotecan (LINO) that has been used in the treatment of cancer. 43mg is approximately 0.06% to 0.09% concentration of LINO, which is an injectable drug used for the treatment of metastatic melanoma and locally advanced soft tissue sarcoma by intra-tumor injection into a tumor site or muscle.
50mg:
Irinotecan is a liposomal drug that contains 50 mg of irinotecan. It is used for the treatment of breast cancer and metastatic melanoma. Liposomal drugs are small particles made up of fat that carry the medicine inside them. They are taken into the cells by receptor-mediated endocytosis and then they get released in the cell interior where they do their work.
Application Insights:
Drugs store was the largest application segment in 2017 and accounted for more than 50% of total revenue. Liposomal irinotecan is used as second line treatment for Cri-du-chat (visceral) cancer after other systemic therapies have failed. The drug has been approved by U.S FDA under IND approval category II which allows its use in combination with carboplatin and etoposide under special conditions of use, such as patients must be able to tolerate high doses of these drugs without any adverse effects.
Hospital is expected to be the fastest growing application segment over the forecast period owing to increasing number of approvals by regulatory authorities, such as EMA and FDA, for new indications or existing ones that require less severe dose escalation or cannot be treated with surgery alone due to limited penetration at a population level across countries including India, China Japan etc.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of patients suffering from cancer and increasing awareness about liposomal formulations are some factors responsible for its largest share. In addition, growing R&D activities by major players to develop novel liposomal formulations is expected to drive the regional market over the forecast period.
Asia Pacific is anticipated to be one of the fastest-growing regions during the forecast years owing to rising healthcare expenditure, improving economic conditions and increasing patient pool in this region. Moreover, availability of less expensive generic drugs due to patent expirations in various countries is also driving growth in this region. China was one such country where patent expirations caused affordability issues for brand name drugs thus leading them t oswitchoverto generic ones; however, irinotecan was not among them because it has a very narrow therapeutic range so its price remained unaffordable even after going into generics (Figure 1).
Growth Factors:
- Increasing incidence of colorectal cancer: The incidence of colorectal cancer is increasing globally due to the changing lifestyle and dietary habits. This will drive the demand for liposomal irinotecan as it is an effective treatment for colorectal cancer.
- Growing awareness about liposomal irinotecan: There is growing awareness among physicians and patients about the benefits of liposomal irinotecan over traditional chemotherapy drugs. This will boost the demand for this drug in the coming years.
- Rising number of clinical trials: A large number of clinical trials are being conducted on liposomal irinotecan which is expected to result in its wider adoption in the near future.
- Technological advancements: The development of new and innovative technologies for delivering chemotherapeutic agents has led to increased use of liposomal irinotecan across different geographies. This trend is likely to continue in the coming years, boosting market growth significantly.. 5) Increasing healthcare expenditure: There has been a significant increase in healthcare expenditure across developed and developing countries, owing to rising prevalence rates of various diseases including cancer
Scope Of The Report
Report Attributes
Report Details
Report Title
Liposomal Irinotecan Market Research Report
By Type
43mg, 50mg
By Application
Hospital, Drugs Store
By Companies
Ipsen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Liposomal Irinotecan Market Report Segments:
The global Liposomal Irinotecan market is segmented on the basis of:
Types
43mg, 50mg
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Drugs Store
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Ipsen
Highlights of The Liposomal Irinotecan Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 43mg
- 50mg
- By Application:
- Hospital
- Drugs Store
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Liposomal Irinotecan Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Liposomal irinotecan is a chemotherapy drug that is administered by injection. It works by killing cancer cells in the body. Liposomal irinotecan is often used to treat metastatic colorectal cancer, pancreatic cancer, and ovarian cancer.
Some of the key players operating in the liposomal irinotecan market are Ipsen.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Liposomal Irinotecan Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Liposomal Irinotecan Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Liposomal Irinotecan Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Liposomal Irinotecan Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Liposomal Irinotecan Market Size & Forecast, 2020-2028
4.5.1 Liposomal Irinotecan Market Size and Y-o-Y Growth
4.5.2 Liposomal Irinotecan Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 43mg
5.2.2 50mg
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Drugs Store
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Liposomal Irinotecan Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Liposomal Irinotecan Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 43mg
9.6.2 50mg
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Drugs Store
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 43mg
10.6.2 50mg
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Drugs Store
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 43mg
11.6.2 50mg
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Drugs Store
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 43mg
12.6.2 50mg
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Drugs Store
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 43mg
13.6.2 50mg
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Drugs Store
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Liposomal Irinotecan Market: Competitive Dashboard
14.2 Global Liposomal Irinotecan Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Ipsen
